Navigation Links
Pain Relief in Just One Visit with Genzyme's Synvisc-One
Date:3/23/2009

Single-injection products will drive the US Hyaluronic Acid Viscosupplementation market to nearly $1 billion by 2013, according to Millennium Research Group

WALTHAM, Mass., March 23 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Orthopedic Biomaterials 2009 report, the US launch of Genzyme Biosurgery's single-injection Synvisc-One will drive procedural growth in the hyaluronic acid (HA) viscosupplementation market. Released to the market in February 2009, Synvisc-One adoption will fuel HA viscosupplementation revenues to reach nearly $1 billion by 2013.

Prior to the launch, HA viscosupplementation treatments were available only in 3-and 5-injection regimens. Over the next several years, many physicians are expected to adopt single-injection products in place of the 3- and 5-injection treatments. Single-injection treatments, which offer greater convenience and less pain, will gain popularity among both patients and physicians over the next five years and will account for approximately one-third of treatments by 2013. With Synvisc-One currently the only approved single-injection treatment, Genzyme Biosurgery is positioned to benefit from this shift in preference.

"The HA viscosupplementation market is the fastest-growing segment of the orthopedic biomaterial market, fueled in particular by the rise of single-injection treatments," says Kevin Flewwelling, Manager of the Orthopedics division at MRG. "Now that Synvisc-One has approval in the US, the door is open for the release of other single-injection products that will be launched through to 2013, driving the high growth in this market."

In addition to HA viscosupplementation, MRG's US Markets for Orthopedic Biomaterials 2009 report covers bone graft substitutes, machined bone interbody devices, cell concentration systems, and knee cartilage repair. The report also provides coverage of all key industry competitors, including AlloSource, Biomet, Blackstone Medical (Orthofix), DePuy, Exactech, Ferring Pharmaceuticals, Genzyme Biosurgery, Integra LifeSciences, LifeNet Health, Medtronic Spinal and Biologics, Musculoskeletal Transplant Foundation, Orthovita, Osiris Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith & Nephew, Stryker, Synthes, Wright Medical Technology, and many more. Other reports in this series cover Europe and Asia Pacific.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
2. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
3. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
6. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
7. MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients
8. invivodata Captures Symptom Relief Data in Endometriosis Trial
9. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
10. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
11. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):